Literature DB >> 11340633

Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study.

B Djavan1, P Mazal, A Zlotta, R Wammack, V Ravery, M Remzi, M Susani, A Borkowski, S Hruby, L Boccon-Gibod, C C Schulman, M Marberger.   

Abstract

PURPOSE: We evaluated pathological features of prostate cancer detected on repeat prostate biopsy in men with a serum total prostate-specific antigen (PSA) level between 4 and 10 ng/ml who were diagnosed with benign prostatic tissue after an initial biopsy and compared them to those cancers detected on initial prostate biopsy.
MATERIALS AND METHODS: In this prospective European prostate cancer detection study, 1,051 men with a total PSA level between 4 and 10 ng/ml underwent transrectal ultrasound (TRUS)-guided sextant biopsy and two additional transition zone biopsies. All subjects whose biopsy samples were negative for prostate cancer (CaP) underwent a repeat biopsy after 6 weeks. Those with clinically localized cancers underwent radical prostatectomy. Pathological and clinical features of patients diagnosed with cancer on either initial or repeat biopsy and clinically organ confined disease who agreed to undergo radical prostatectomy were compared.
RESULTS: Initial biopsy was positive (CaP) in 231 of 1,051 enrolled subjects and negative (benign histology) in 820 subjects. Of these 820 subjects, CaP was detected in 10% (83/820) upon repeat biopsy. Of cancers detected on initial and repeat biopsy, 148/231 (64%) and 56/83 (67.5%) had clinically localized disease, respectively, and were offered radical prostatectomy. 10/148 (6.7%) and 3/56 (5.3%), respectively, opted for radiation therapy and thus, 138/148 (93.3%) and 53/56 (94.7%), respectively, underwent radical retropubic prostatectomy. There were statistically significant differences with respect to multifocality (P = 0.009) and cancer location (P < 0.001) with cancers on repeat biopsy showing a lower rate of multifocality and a more apico-dorsal location. In contrast, there were no differences with respect to stage (P = 0.2), Gleason score (P = 0.36), percentage Gleason grade 4/5 (P = 0.1), serum PSA (P = 0.62), and patient age (P = 0.517).
CONCLUSIONS: At least 10% of patients with negative prostatic biopsy results will be diagnosed with CaP on repeat biopsy. Despite differences in location and multifocality, pathological and biochemical features of cancers detected on initial and repeat biopsy are similar, suggesting similar biological behavior and thus advocating for a repeat prostate biopsy in case of a negative finding on initial biopsy. Cancers missed on initial biopsy and subsequently detected on repeat biopsy are located in a more apico-dorsal location. Repeat biopsies should thus be directed to this rather spared area in order to improve cancer detection rates. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340633     DOI: 10.1002/pros.1053

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  15 in total

1.  Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection.

Authors:  D M Somford; W Vreuls; T S Jansen; J P van Basten; H Vergunst
Journal:  World J Urol       Date:  2013-07-20       Impact factor: 4.226

2.  Value of enhanced transrectal ultrasound targeted biopsy for prostate cancer diagnosis: a retrospective data analysis.

Authors:  Friedrich Aigner; Georg Schäfer; Eberhard Steiner; Werner Jaschke; Wolfgang Horninger; Thomas R W Herrmann; Udo Nagele; Ethan J Halpern; Ferdinand Frauscher
Journal:  World J Urol       Date:  2011-12-18       Impact factor: 4.226

Review 3.  Contrast specific imaging in the detection and localization of prostate cancer.

Authors:  Hessel Wijkstra; Margot H Wink; Jean J M C H de la Rosette
Journal:  World J Urol       Date:  2004-10-05       Impact factor: 4.226

4.  The Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy.

Authors:  Dae Keun Kim; Sang Jin Kim; Hong Sang Moon; Sung Yul Park; Yong Tae Kim; Hong Yong Choi; Tchun Yong Lee; Hae Young Park
Journal:  Korean J Urol       Date:  2010-05-19

5.  A review of repeat prostate biopsies and the influence of technique on cancer detection: our experience.

Authors:  M R Quinlan; R G Casey; R Flynn; R Grainger; T E D McDermott; J A Thornhill
Journal:  Ir J Med Sci       Date:  2009-06-04       Impact factor: 1.568

Review 6.  [Transrectal ultrasound-guided punch biopsies of the prostate. Indication, technique, results, and complications].

Authors:  J Palisaar; T Eggert; M Graefen; A Haese; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

7.  Methylation of the RARB gene increases prostate cancer risk in black Americans.

Authors:  Deliang Tang; Oleksandr N Kryvenko; Nicoleta Mitrache; Kieu C Do; Michelle Jankowski; Dhananjay A Chitale; Sheri Trudeau; Andrew Rundle; Steven A Belinsky; Benjamin A Rybicki
Journal:  J Urol       Date:  2013-01-30       Impact factor: 7.450

8.  Pathological correlation between needle biopsy and radical prostatectomy specimen in patients with localized prostate cancer.

Authors:  Muhammad A Bulbul; Yaser El-Hout; Maurice Haddad; Ayman Tawil; Ali Houjaij; Nizar Bou Diab; Oussama Darwish
Journal:  Can Urol Assoc J       Date:  2007-09       Impact factor: 1.862

9.  Increased rate of positive biopsies using a combination of MR-Tomography, spectroscopy and diffusion-weighted magnetic resonance imaging prior to prostate biopsies in patients with persistent elevated prostate-specific antigen values: A retrospective analysis.

Authors:  A Lunacek; J Simon; R Bernt; M Huber; E Plas; C Mrstik
Journal:  Urol Ann       Date:  2013-04

10.  Differences in Postoperative Pathological Outcomes between Prostate Cancers Diagnosed at Initial and Repeat Biopsy.

Authors:  In Ho Khang; Yun Beom Kim; Seung Ok Yang; Jeong Ki Lee; Tae Young Jung
Journal:  Korean J Urol       Date:  2012-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.